North China Pharmaceutical Company.Ltd (SHA:600812)
China
· Delayed Price · Currency is CNY 5.81
-0.20 (-3.33%)
Mar 10, 2026, 11:30 AM CST
SHA:600812 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 10,312 | 8,870 | 9,780 | 10,981 | 20,452 | 16,781 | Upgrade
|
| Market Cap Growth | -5.35% | -9.30% | -10.94% | -46.31% | 21.87% | 4.57% | Upgrade
|
| Enterprise Value | 21,011 | 19,926 | 20,598 | 20,895 | 30,116 | 25,631 | Upgrade
|
| Last Close Price | 6.01 | 5.15 | 5.66 | 6.36 | 11.73 | 10.10 | Upgrade
|
| PE Ratio | 56.72 | 69.85 | 1999.79 | - | 1092.06 | 172.42 | Upgrade
|
| Forward PE | - | 40.53 | 40.53 | 40.53 | 40.53 | 40.53 | Upgrade
|
| PS Ratio | 1.05 | 0.90 | 0.97 | 1.05 | 1.97 | 1.46 | Upgrade
|
| PB Ratio | 1.55 | 1.33 | 1.56 | 1.76 | 2.91 | 2.38 | Upgrade
|
| P/TBV Ratio | 3.88 | 3.37 | 2.93 | 3.01 | 4.32 | 3.44 | Upgrade
|
| P/FCF Ratio | 68.62 | 19.92 | 24.37 | 24.14 | 40.68 | - | Upgrade
|
| P/OCF Ratio | 12.38 | 7.21 | 9.55 | 10.93 | 19.47 | 22.31 | Upgrade
|
| EV/Sales Ratio | 2.15 | 2.02 | 2.04 | 1.99 | 2.90 | 2.23 | Upgrade
|
| EV/EBITDA Ratio | 13.65 | 13.64 | 16.15 | 15.51 | 24.60 | 21.04 | Upgrade
|
| EV/EBIT Ratio | 32.69 | 29.61 | 38.40 | 32.92 | 50.18 | 42.87 | Upgrade
|
| EV/FCF Ratio | 139.82 | 44.74 | 51.34 | 45.94 | 59.90 | - | Upgrade
|
| Debt / Equity Ratio | 1.67 | 1.72 | 1.78 | 1.77 | 1.96 | 1.62 | Upgrade
|
| Debt / EBITDA Ratio | 7.24 | 7.47 | 7.88 | 7.81 | 10.57 | 9.40 | Upgrade
|
| Debt / FCF Ratio | 74.11 | 25.71 | 27.78 | 24.29 | 27.40 | - | Upgrade
|
| Net Debt / Equity Ratio | 1.43 | 1.47 | 1.62 | 1.50 | 1.21 | 0.93 | Upgrade
|
| Net Debt / EBITDA Ratio | 6.49 | 6.70 | 7.97 | 6.95 | 6.92 | 5.37 | Upgrade
|
| Net Debt / FCF Ratio | 63.43 | 21.98 | 25.32 | 20.59 | 16.85 | -25.66 | Upgrade
|
| Asset Turnover | 0.45 | 0.47 | 0.48 | 0.46 | 0.43 | 0.54 | Upgrade
|
| Inventory Turnover | 2.87 | 2.63 | 2.69 | 2.87 | 2.76 | 3.17 | Upgrade
|
| Quick Ratio | 0.47 | 0.50 | 0.49 | 0.49 | 0.70 | 0.80 | Upgrade
|
| Current Ratio | 0.67 | 0.75 | 0.78 | 0.72 | 0.89 | 1.03 | Upgrade
|
| Return on Equity (ROE) | 4.22% | 3.32% | 0.79% | -10.25% | 0.50% | 1.63% | Upgrade
|
| Return on Assets (ROA) | 1.86% | 1.98% | 1.59% | 1.72% | 1.54% | 1.74% | Upgrade
|
| Return on Invested Capital (ROIC) | 2.99% | 2.84% | 1.04% | 4.08% | 1.08% | 2.44% | Upgrade
|
| Return on Capital Employed (ROCE) | 7.00% | 6.40% | 5.00% | 7.20% | 5.60% | 4.90% | Upgrade
|
| Earnings Yield | 1.78% | 1.43% | 0.05% | -6.28% | 0.09% | 0.58% | Upgrade
|
| FCF Yield | 1.46% | 5.02% | 4.10% | 4.14% | 2.46% | -1.52% | Upgrade
|
| Dividend Yield | 0.54% | 0.58% | 0.18% | - | 0.51% | 0.30% | Upgrade
|
| Payout Ratio | 241.49% | 369.37% | 10195.21% | - | 3987.68% | 674.90% | Upgrade
|
| Buyback Yield / Dilution | -7.99% | -5.27% | 4.92% | -0.70% | -4.96% | 0.12% | Upgrade
|
| Total Shareholder Return | -7.45% | -4.69% | 5.10% | -0.70% | -4.45% | 0.42% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.